Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Cases. Jun 16, 2013; 1(3): 106-107
Published online Jun 16, 2013. doi: 10.12998/wjcc.v1.i3.106
Published online Jun 16, 2013. doi: 10.12998/wjcc.v1.i3.106
Hepatitis C treatment with triple therapy in a patient with hemophilia A
Gurshawn Singh, Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Reuben Sass, Rayan Alamiry, Nizar Zein, Naim Alkhouri, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
Author contributions: Singh G and Alkhouri N designed the report; Singh G, Sass R and Alamiry R analyzed data; Alkhouri N was the attending doctor for the patient; Singh G, Zein N and Alkhouri N wrote the paper.
Correspondence to: Naim Alkhouri, MD, Department of Gastroenterology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, United States. alkhoun@ccf.org
Telephone: +1-216-4449000 Fax: +1-216-4442974
Received: February 25, 2013
Revised: April 17, 2013
Accepted: May 8, 2013
Published online: June 16, 2013
Processing time: 107 Days and 5 Hours
Revised: April 17, 2013
Accepted: May 8, 2013
Published online: June 16, 2013
Processing time: 107 Days and 5 Hours
Core Tip
Core tip: This is a case of a patient who has Hemophilia A with factor VIII inhibitor and chronic hepatitis C. After successfully treating the patient’s hepatitis C with protease-inhibitor based triple therapy and achieving response-guided therapy with negative hepatitis C virus RNA after week 4, the patient’s need for recombinant factor VIII decreased significantly.